Biologic Agent Use Varies Inversely with Age at Diagnosis in Crohn’s Disease

Feagins, Linda A.; Spechler, Stuart J.

doi:10.1007/s10620-010-1397-9

Cited by 7 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study of 393 geriatric IBD patients, up to 32% were receiving long‐term corticosteroids with only 6% receiving immunomodulators and 3% biologics . Finally, a Veteran's Administration Hospital survey found that biologic use varied inversely with age at diagnosis, with no patient over the age of 70 years at diagnosis receiving anti‐TNF therapy compared to 67% of patients diagnosed before the age of 40 . In summary, current approach to drug therapy in the elderly is to ‘start low − go slow’ before reassessing more aggressive therapy (immunomodulators, biologics, surgery)…”

Section: Medical Treatmentmentioning

confidence: 99%

Systematic review with meta‐analysis: inflammatory bowel disease in the elderly

Gisbert

Chaparro

2014

Aliment Pharmacol Ther

143

102

View full text Add to dashboard Cite

show abstract

Section: Medical Treatmentmentioning

confidence: 99%

Systematic review with meta‐analysis: inflammatory bowel disease in the elderly

Gisbert

Chaparro

2014

Aliment Pharmacol Ther

143

102

View full text Add to dashboard Cite

show abstract

“…It had been revealed that in CD patients the use of biologic agent varied inversely with age at diagnosis. 17 Compared with patients in group A3, we found that patients in group A2 were more likely to use biological agents. The Italian group for the study of IBD found that when CD patients were classified by young adult-onset (16–39 years), adult-onset (40–64 years), and late-onset (≥65 years), the three age groups had an equal need for surgery and using of steroids.…”

Section: Discussionmentioning

confidence: 57%

Clinical Features of Crohn’s Disease Stratified by Age at Diagnosis According to Montreal Classification

Xiang¹,

Li²,

Liu³

et al. 2023

JIR

View full text Add to dashboard Cite

Aim The differences of clinical characteristics stratified by age at diagnosis especially according to Montreal classification were rarely studied in China. This study aimed to evaluate and compare the clinical features in various groups of CD patients stratified by age at diagnosis. Methods A cross-sectional study of CD patients was conducted through a stratified sampling according to Montreal classification. Patients were divided into three groups by age at diagnosis: group A1 (<17 years old), group A2 (17 to 40 years old), and group A3 (>40 years old). The clinical characteristics, laboratory tests, radiographic, and endoscopic features were analyzed by statistics. Results We enrolled 259 CD patients for the study. There was male predominance under 40 years old. Compared to group A1, more female patients were presented in group A3. There were more patients had perianal fistulas in group A1 compared to group A2 and group A3. Compared with group A1, patients in group A2 were associated with lower total protein (TP) levels. The mean TP and platelet count (PC) levels in group A3 were lower than group A1. Patients in group A1 had a lower rate of stricturing (B2) disease behavior than group A2 and group A3, and patients in group A3 who had a B2 disease behavior were higher than group A2. Those differences could guide early treatment or inventions for CD patients who might progress to a more complex disease behavior. Conclusion CD patients stratified by age at diagnosis according to Montreal classification had different clinical symptoms, laboratory test results as well as disease locations and behaviors.

show abstract